GlassScriptPhysician profile
William G Ogg
NPI 1881816619
$3,348.23
in general payments reported to CMS, 2019-2025
26 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $156 · 2021: $592 · 2022: $715 · 2023: $571 · 2024: $551 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.64 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $315.21 | 2019-2025 | |
| Boston Scientific Corporation | $207.24 | 2021-2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $177.54 | 2019-2025 | Entyvio |
| Genzyme Corporation | $135.87 | 2023-2025 | |
| Evoke Pharma, INC. | $135.26 | 2022-2023 | Gimoti |
| Celgene Corporation | $134.89 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $125.36 | 2019-2024 | Stelara |
| Nestle Healthcare Nutrition INC. | $80.41 | 2021-2023 | |
| Pfizer INC. | $72.24 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $71.35 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $64.12 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $55.53 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $43.49 | 2023-2024 | Dificid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $38.48 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $37.81 | 2019-2022 | |
| Qol Medical, LLC | $35.80 | 2022-2024 | Sucraid |
| Mallinckrodt Hospital Products INC. | $25.80 | 2022 | |
| Erbe USA INC | $24.67 | 2025 | Vio300 |
| Regeneron Healthcare Solutions, INC. | $22.81 | 2023 | Dupixent |
| Lilly USA, LLC | $20.77 | 2023 | |
| Daiichi Sankyo INC. | $13.96 | 2020 | |
| Novo Nordisk INC | $13.49 | 2025 | Saxenda, Wegovy |
| Enterra Medical, INC. | $13.27 | 2022 | |
| Medtronic, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.